+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2025-2030- Product Image
Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5887479
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dilated Cardiomyopathy Therapeutics Market grew from USD 421.50 million in 2023 to USD 456.76 million in 2024. It is expected to continue growing at a CAGR of 7.79%, reaching USD 712.65 million by 2030.

Dilated Cardiomyopathy (DCM) is a progressive condition characterized by the enlargement and weakening of the heart's ventricles, leading to impaired cardiac output. The therapeutic landscape for DCM focuses on managing symptoms, improving heart function, and slowing disease progression. The necessity of DCM therapeutics stems from the chronic nature of the disease and its potential for severe complications, including heart failure and arrhythmias. These treatments are applicable in hospital settings, outpatient clinics, and specialized cardiac centers with patient end-users, consisting of individuals diagnosed with DCM. Key market growth factors include the rising prevalence of cardiovascular diseases, advancements in genetic therapies, and increasing investment in cardiac-specific pharmaceuticals. Opportunities within this market are notably influenced by the development of innovative therapies, such as gene modification technologies and personalized medicine approaches. Companies can capitalize on these opportunities by investing in research and partnerships that enhance their understanding of cardiomyocyte biology and the genetic basis of DCM. Despite these opportunities, market growth is challenged by high costs of treatment development, regulatory hurdles, and the limited availability of large-scale clinical trial data. Furthermore, the heterogeneity of DCM presents a significant hurdle, necessitating a tailored approach to treatment modalities. Innovation in this field can be driven by focusing on non-traditional areas of research, such as AI-driven drug discovery, biomarkers for early diagnosis, and the integration of telemedicine to enhance patient management. The competitive landscape remains intense, with numerous established pharmaceutical players and biotech startups vying for breakthroughs in this segment. Strategically, firms should prioritize collaborations with research institutions, leverage data analytics for patient stratification, and advocate for policies that support accelerated approval pathways for promising therapies. Thus, while the DCM therapeutics market holds immense potential, it mandates strategic investment and innovation to overcome inherent challenges.

Understanding Market Dynamics in the Dilated Cardiomyopathy Therapeutics Market

The Dilated Cardiomyopathy Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Prevalence of cardiovascular diseases and the need for effective treatments
    • Inclination toward early diagnosis and treatment of diseases
    • Government initiatives and programs to raise awareness regarding cardiovascular diseases
  • Market Restraints
    • High cost of dilated-cardiomyopathy therapeutics
  • Market Opportunities
    • Applications of precision medicine in the management of dilated cardiomyopathy
    • Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
  • Market Challenges
    • Side effects associated with the dilated-cardiomyopathy medications

Exploring Porter’s Five Forces for the Dilated Cardiomyopathy Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Dilated Cardiomyopathy Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Dilated Cardiomyopathy Therapeutics Market

External macro-environmental factors deeply influence the performance of the Dilated Cardiomyopathy Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Dilated Cardiomyopathy Therapeutics Market

The Dilated Cardiomyopathy Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Dilated Cardiomyopathy Therapeutics Market

The Dilated Cardiomyopathy Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Dilated Cardiomyopathy Therapeutics Market

The Dilated Cardiomyopathy Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dilated Cardiomyopathy Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, The Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dilated Cardiomyopathy Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug class
    • Aldosterone antagonists
    • Angiotensin II Receptor Blockers
    • Angiotensin-converting enzyme (ACE) Inhibitors
    • Beta-blockers
  • Treatment Type
    • Cardioverter-Defibrillators
    • Heart Pumps
    • Implantable Devices
    • Medication
  • Route of Administration
    • Oral
    • Parenteral
  • End-User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of cardiovascular diseases and the need for effective treatments
5.1.1.2. Inclination toward early diagnosis and treatment of diseases
5.1.1.3. Government initiatives and programs to raise awareness regarding cardiovascular diseases
5.1.2. Restraints
5.1.2.1. High cost of dilated-cardiomyopathy therapeutics
5.1.3. Opportunities
5.1.3.1. Applications of precision medicine in the management of dilated cardiomyopathy
5.1.3.2. Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
5.1.4. Challenges
5.1.4.1. Side effects associated with the dilated-cardiomyopathy medications
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Dilated Cardiomyopathy Therapeutics Market, by Drug class
6.1. Introduction
6.2. Aldosterone antagonists
6.3. Angiotensin II Receptor Blockers
6.4. Angiotensin-converting enzyme (ACE) Inhibitors
6.5. Beta-blockers
7. Dilated Cardiomyopathy Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Cardioverter-Defibrillators
7.3. Heart Pumps
7.4. Implantable Devices
7.5. Medication
8. Dilated Cardiomyopathy Therapeutics Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Dilated Cardiomyopathy Therapeutics Market, by End-User
9.1. Introduction
9.2. Hospitals
9.3. Research Institutes
9.4. Specialty Clinics
10. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Americas Dilated Cardiomyopathy Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Dilated Cardiomyopathy Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Dilated Cardiomyopathy Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 132. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 238. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Dilated Cardiomyopathy Therapeutics Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc
  • C.H. Boehringer Sohn AG & Co. KG
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co, Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sarepta Therapeutics
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol-Myers Squibb Company
  • The Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 456.76 Million
Forecasted Market Value ( USD ) by 2030 $ 712.65 Million
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region - Product Image

Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region

  • Report
  • 200 Pages
  • Global
From
Dilated Cardiomyopathy Therapeutics - Global Strategic Business Report - Product Image

Dilated Cardiomyopathy Therapeutics - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Cardiomyopathy Therapies - Global Strategic Business Report - Product Image

Cardiomyopathy Therapies - Global Strategic Business Report

  • Report
  • 250 Pages
  • Global
From
Dilated Cardiomyopathy (DCM) - Epidemiology Forecast - 2034 - Product Image

Dilated Cardiomyopathy (DCM) - Epidemiology Forecast - 2034

  • Report
  • 80 Pages
  • Global
From
Hypertrophic Cardiomyopathy (HCM) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Hypertrophic Cardiomyopathy (HCM) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Cardiomyopathy Drug Market

The Cardiomyopathy Drug market is a subset of the Cardiovascular Drugs market, focusing on drugs used to treat cardiomyopathy, a condition in which the heart muscle becomes weakened or damaged. These drugs are used to reduce symptoms, improve heart function, and reduce the risk of complications. Commonly used drugs include beta-blockers, ACE inhibitors, angiotensin receptor blockers, and diuretics. Other treatments may include lifestyle changes, such as diet and exercise, and surgery. The Cardiomyopathy Drug market is highly competitive, with many companies offering a variety of treatments. Major players in the market include Pfizer, Novartis, Sanofi, Merck, and GlaxoSmithKline. Other companies include AstraZeneca, Bristol-Myers Squibb, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.